Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) EBT (2018 - 2025)

Historic EBT for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $23.0 million.

  • TransMedics' EBT rose 44254.42% to $23.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.9 million, marking a year-over-year increase of 18766.38%. This contributed to the annual value of $35.8 million for FY2024, which is 23233.23% up from last year.
  • Per TransMedics' latest filing, its EBT stood at $23.0 million for Q3 2025, which was up 44254.42% from $36.2 million recorded in Q2 2025.
  • In the past 5 years, TransMedics' EBT ranged from a high of $36.2 million in Q2 2025 and a low of -$26.9 million during Q3 2023
  • In the last 5 years, TransMedics' EBT had a median value of -$2.6 million in 2023 and averaged $731263.2.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 26356.15% in 2023, then skyrocketed by 134010.2% in 2024.
  • Over the past 5 years, TransMedics' EBT (Quarter) stood at -$12.8 million in 2021, then soared by 45.66% to -$7.0 million in 2022, then soared by 150.29% to $3.5 million in 2023, then skyrocketed by 99.91% to $7.0 million in 2024, then skyrocketed by 229.53% to $23.0 million in 2025.
  • Its EBT stands at $23.0 million for Q3 2025, versus $36.2 million for Q2 2025 and $26.7 million for Q1 2025.